Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June 2015
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
The majority of the articles from the May 2013 CHEST Supplement "Lung cancer guidelines" are online only. The individual chapters are only available as electronic files. The print edition only includes the following articles which are free online to view: Disclaimer; Panel List; Executive Summary…
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24-31 May 2016
This documentary introduces us to Stephen Jenkinson, once the leader of a palliative care counselling team at Toronto's Mount Sinai Hospital. Through his daytime job, he has been at the deathbed of well over 1,000 people. What he sees over and over, he says, is "a wretched anxiety and an existentia…
Table of Contents:; 1. Immunotherapy administration; 2. Immunotherapy; 3. Cancer immunotherapy; 4. CAR T-cell therapy; 5. Cytokine release syndrome; 6. Developming infrastructure; 7. Immunotherapy toxicities; 8. Checkpoint inhibitors; 9. Toxicity managment; 10.Oncolytic viruses
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library | Available |